MARKET

HRMY

HRMY

Harmony Biosciences Holdings, Inc.
NASDAQ
33.58
+0.06
+0.18%
After Hours: 31.74 -1.84 -5.48% 18:01 03/28 EDT
OPEN
33.52
PREV CLOSE
33.52
HIGH
33.98
LOW
32.62
VOLUME
303.55K
TURNOVER
0
52 WEEK HIGH
42.69
52 WEEK LOW
18.61
MARKET CAP
1.91B
P/E (TTM)
15.73
1D
5D
1M
3M
1Y
5Y
Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
Harmony Biosciences (NASDAQ:HRMY) underwent analysis by 8 analysts in the last quarter. The company has an average price target of $42.62 and a 12-month average of $28.00. The firm is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases.
Benzinga · 13h ago
Harmony Biosciences Price Target Maintained With a $49.00/Share by Cantor Fitzgerald
Dow Jones · 14h ago
Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $49 Price Target
Benzinga · 14h ago
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Astria Therapeutics (ATXS)
TipRanks · 3d ago
Weekly Report: what happened at HRMY last week (0318-0322)?
Weekly Report · 3d ago
IXJ: Healthcare Sector Dashboard For March
IShares Global Healthcare ETF is overvalued by about 13% relative to 11-year averages. Healthcare equipment has the worst value and quality scores. The healthcare sector is the most overvalued in the U.S. In March 2024. This monthly article series shows a dashboard with aggregate industry metrics in healthcare.
Seeking Alpha · 03/18 18:07
Weekly Report: what happened at HRMY last week (0311-0315)?
Weekly Report · 03/18 10:19
Harmony Biosciences Holdings Breaks Above 200-Day Moving Average - Bullish for HRMY
NASDAQ · 03/15 21:05
More
About HRMY
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action (MOA) designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a wake-promoting neurotransmitter. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol.

Webull offers Harmony Biosciences Holdings Inc stock information, including NASDAQ: HRMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HRMY stock methods without spending real money on the virtual paper trading platform.